

# Annals of the Rheumatic Diseases

The EULAR Journal



Annual European Congress of  
**RHEUMATOLOGY**

**EULAR 2017**

Madrid, 14–17 June 2017

Abstracts

# Annals of the Rheumatic Diseases

---

Annual European Congress of Rheumatology

14 – 17 June, 2017

Madrid, Spain

**Abstracts**

The EULAR Journal

**Editor**

Tore K Kvien (Norway)

**Associate Editors**

Francis Berenbaum (France)  
 Johannes Bijlsma (The Netherlands)  
 Dimitrios Boumpas (Greece)  
 Gerd Burmester (Germany)  
 Mary Crow (USA)  
 Iain McInnes (UK)  
 David Pisetsky (USA)

**Methodological and Statistical Advisor**

Stian Lydersen (Norway)

**Graphical Advisor**

Maarten Boers (The Netherlands)

**Social Media Advisors**

Alessia Alunno (Italy)  
 Mary Canavan (Ireland)  
 Meghna Jani (UK)  
 Elena Nikiphorou (UK)  
 Paul Studenic (Austria)

**Guidelines for Authors and Reviewers**

Full instructions are available online at <http://ard.bmj.com/pages/authors>. Articles must be submitted electronically at <http://mc.manuscriptcentral.com/ard>. Authors retain copyright but are required to grant ARD an exclusive licence to publish. (<http://authors.bmj.com/submitting-your-paper/copyright-and-authors-rights>).

# Annals of the Rheumatic Diseases publishes original work on all aspects of rheumatology and disorders of connective tissue. Laboratory and clinical studies are equally welcome

**Editorial Board**

Daniel Aletaha (Austria)  
 Matthew Brown (Australia)  
 Loreto Carmona (Spain)  
 Carlo Chizzolini (Switzerland)  
 Bernard Combe (France)  
 Philip Conaghan (UK)  
 Maurizio Cutolo (Italy)  
 László Czirják (Hungary)  
 Nicola Dalbeth (New Zealand)  
 Oliver Distler (Switzerland)  
 Thomas Dörner (Germany)  
 Dirk Elewaut (Belgium)  
 Gary Firestein (USA)  
 David Fox (USA)  
 Sherine Gabriel (USA)  
 Mary Goldring (USA)  
 Juan Gómez-Reino (Spain)  
 Walter Grassi (Italy)  
 Wolfgang Gross (Germany)  
 Francis Guillemin (France)  
 Ahmet Gül (Turkey)  
 Kåre Birger Hagen (Norway)  
 Frederic Houssiau (Belgium)  
 Tom Huizinga (The Netherlands)  
 Roland Jonsson (Norway)  
 Mariana Kaplan (USA)  
 George Kollias (Greece)  
 Robert Landewé (The Netherlands)  
 Zhan-Guo Li (China)  
 Rik Lories (Belgium)  
 Ingrid Lundberg (Sweden)  
 Gary MacFarlane (UK)  
 Xavier Mariette (France)

Alberto Martini (Italy)  
 Włodzimierz Maslinski (Poland)  
 Marco Mattucci Cerinic (Italy)  
 Dennis McGonagle (UK)  
 Pier-Luigi Meroni (Italy)  
 Pierre Miossec (France)  
 Timothy Niewold (USA)  
 Mike Nurmohamed (The Netherlands)  
 Monika Østensen (Switzerland)  
 Mikkel Østergaard (Denmark)  
 Costantino Pitzalis (UK)  
 Berent Prakken (The Netherlands)  
 Lars Rönnblom (Sweden)  
 Jane Salmon (USA)  
 Georg Schett (Germany)  
 José da Silva (Portugal)  
 Hendrik Schulze-Koops (Germany)  
 Nan Shen (China)  
 Alexander So (Switzerland)  
 Tuulikki Sokka (Finland)  
 Deborah Symmons (UK)  
 Tsutomu Takeuchi (Japan)  
 Yoshiya Tanaka (Japan)  
 Alan Tyndall (Switzerland)  
 John Varga (USA)  
 Dimitrios Vassilopoulos (Greece)  
 Douglas Veale (Ireland)  
 Jiri Vencovsky (Czech Republic)  
 Ronald van Vollenhoven (Sweden)  
 Michael Ward (USA)  
 Kevin Winthrop (USA)  
 Kazuhiko Yamamoto (Japan)

**Advisory Committee**

Wim van den Berg (The Netherlands)  
 Stefano Bombardieri (Italy)  
 Ferdinand Breedveld (The Netherlands)  
 Leslie Crofford (USA)  
 Michael Doherty (UK)  
 Maxime Dougados (France)  
 Paul Emery (UK)  
 Daniel Furst (USA)  
 Steffen Gay (Switzerland)  
 Désirée van der Heijde (The Netherlands)  
 Marc Hochberg (USA)  
 Joachim Kalden (Germany)  
 Edward Keystone (Canada)  
 Lars Klareskog (Sweden)  
 Peter Lipsky (USA)

Stefan Lohmander (Sweden)  
 Sir Ravinder Maini (UK)  
 Emilio Martín-Mola (Spain)  
 Haralampos Moutsopoulos (Greece)  
 James O'Dell (USA)  
 Karel Pavelka (Czech Republic)  
 Leo van de Putte (The Netherlands)  
 Jozef Rovensky (Slovakia)  
 Yehuda Shoenfeld (Israel)  
 Josef Smolen (Austria)  
 Walther van Venrooij (The Netherlands)  
 Michael Weinblatt (USA)  
 Frank Wollheim (Sweden)  
 Anthony Woolf (UK)

**Contact Details**

**Editorial Office**

Annals of the Rheumatic Diseases  
 BMJ Publishing Group Ltd  
 BMA House  
 Tavistock Square  
 London WC1H 9JR, UK  
 T: +44 (0)20 7383 6250  
 E: [ard@bmj.com](mailto:ard@bmj.com)

**Permissions**

<http://www.bmj.com/company/products-services/rights-and-licensing/permissions>

**Supplement Enquiries**

T: +44 (0)20 7383 6057  
 E: [journals@bmj.com](mailto:journals@bmj.com)

**Subscriptions**

For all subscription enquiries and orders  
 T: +44 (0)20 7111 1105  
 E: <http://ard.bmj.com/pages/subscribe>

**Display Advertising Sales**

Sophie Fitzsimmons  
 T: +44 (0)20 7383 6783  
 E: [sftzsimmons@bmj.com](mailto:sftzsimmons@bmj.com)  
<http://www.bmj.com/company/raise-visibility-and-reach>

**Online Advertising Sales**

Marc Clifford  
 T: +44 (0) 20 7383 6161  
 E: [mclifford@bmj.com](mailto:mclifford@bmj.com)  
<http://www.bmj.com/company/raise-visibility-and-reach>

**Display & Online Advertising Sales (USA)**

American Medical Communications (AMC)  
 T: +1 732 490 5530  
 E: [jloughran@americanmedicalcomm.com](mailto:jloughran@americanmedicalcomm.com)

**Author Reprints**

Reprints Administrator  
 E: [admin.reprints@bmj.com](mailto:admin.reprints@bmj.com)

**Commercial Reprints (except USA & Canada)**

Nadia Gurney-Randall  
 T: +44 (0)20 8445 5825  
 M: +44 07866 262344  
 E: [ngurneyrandall@bmj.com](mailto:ngurneyrandall@bmj.com)

**Commercial Reprints (USA & Canada)**

Ray Thibodeau  
 T: +1 267 895 1758  
 M: +1 215 933 8484  
 E: [ray.thibodeau@contentednet.com](mailto:ray.thibodeau@contentednet.com)

**EULAR**

EULAR Executive Secretariat  
 Seestrasse 240, 8802 Kilchberg, Switzerland  
 E: [eular@eular.org](mailto:eular@eular.org)  
[www.eular.org](http://www.eular.org)

**For all other ARD contacts**

<http://ard.bmj.com/contact-us>

**Subscription Information**

ARD is published monthly; subscribers receive all supplements  
 ISSN 0003-4967 (print); 1468-2060 (online)

**Institutional Rates 2017**

**Print**  
 £939; US\$1832; €1268

**Online**

Site licences are priced on FTE basis and allow access by the whole institution. Details available online at <http://journals.bmj.com/content/subscribers> or contact the Subscription Manager in the UK (see above right)

Personal print or online only and institutional print subscriptions may be purchased online at <http://journals.bmj.com/content/subscribers> (payment by Visa/Mastercard only)

Residents of some EC countries must pay VAT; for details, call us or visit <http://journals.bmj.com/content/subscribers>

**Personal Rates 2017**

**Print** (includes online access at no additional cost)  
 £387; US\$755; €523

**Online only**  
 £164; US\$320; €222

**EULAR congress delegates**

Delegates receive a Continuous Professional Development package that includes a 12 month complimentary subscription to ARD in print and/or online

AB0021–AB0025	Innate immunity in rheumatic diseases .....	1054
AB0026–AB0058	Cytokines and inflammatory mediators .....	1055
AB0059–AB0075	Cartilage, synovium and osteoimmunology .....	1067
AB0076–AB0111	Rheumatoid arthritis - etiology, pathogenesis and animal models .....	1073
AB0112–AB0120	Spondyloarthritis - etiology, pathogenesis and animal models .....	1085
AB0121–AB0163	SLE, Sjögren's and APS - etiology, pathogenesis and animal models .....	1089
AB0164–AB0186	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models .....	1104
AB0187–AB0188	Basic science in paediatric rheumatology .....	1112
AB0189–AB0289	Rheumatoid arthritis - prognosis, predictors and outcome .....	1113
AB0290–AB0373	Rheumatoid arthritis - comorbidity and clinical aspects .....	1149
AB0374–AB0394	Rheumatoid arthritis - anti-TNF therapy .....	1179
AB0395–AB0416	Rheumatoid arthritis - other biologic treatment .....	1186
AB0417–AB0441	Rheumatoid arthritis - non biologic treatment .....	1196
AB0442–AB0470	SLE, Sjögren's and APS - treatment .....	1204
AB0471–AB0548	SLE, Sjögren's and APS - clinical aspects (other than treatment) .....	1215
AB0549–AB0597	Vasculitis .....	1243
AB0598–AB0682	Scleroderma, myositis and related syndromes .....	1260
AB0683–AB0708	Spondyloarthritis - treatment .....	1292
AB0709–AB0736	Spondyloarthritis - clinical aspects (other than treatment) .....	1302
AB0737–AB0794	Psoriatic arthritis .....	1312
AB0795–AB0819	Osteoarthritis .....	1336
AB0820–AB0860	Osteoporosis .....	1345
AB0861–AB0901	Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis ..	1357
AB0902–AB0922	Infection-related rheumatic diseases .....	1371
AB0923–AB0932	Fibromyalgia .....	1378
AB0933–AB0943	Back pain, mechanical musculoskeletal problems, local soft tissue disorders .....	1382
AB0944–AB0975	Paediatric rheumatology .....	1385
AB0976–AB0996	Other orphan diseases .....	1396
AB0997–AB1074	Diagnostics and imaging procedures .....	1403
AB1075–AB1115	Public health, health services research and health economics .....	1431
AB1116–AB1160	Epidemiology, risk factors for disease or disease progression .....	1446
AB1161–AB1176	Validation of outcome measures and biomarkers .....	1461
AB1177–AB1182	Rehabilitation .....	1467
AB1183–AB1194	Education .....	1469

## Health Professionals in Rheumatology Abstracts

### Oral Presentations

#### Wednesday, 14 June 2017

OP0009-HPR	Wearable technologies in 21 <sup>st</sup> century healthcare .....	53
OP0055-HPR	Rehabilitation and modern drug treatment - needs and challenges .....	73

#### Thursday, 15 June 2017

OP0138-HPR–OP0145-HPR	HPR mind over matter - patients perspectives .....	110
OP0209-HPR	What to do about comorbidity? .....	139

#### Friday, 16 June 2017

OP0254-HPR–OP0261-HPR	HPR move to improve .....	161
OP0314-HPR	Fighting osteoporosis fragilities .....	185

#### Saturday, 17 June 2017

OP0337-HPR	Trials and tribulations of medication adherence .....	194
OP0344-HPR	Closing the gap between objective measures and self-report in fibromyalgia .....	198
OP0347-HPR	Showcasing the EULAR Online Course for Health Professionals .....	199

**Conclusions:** In our series, biological therapy, especially IFX and ADA, is effective and relatively safe in patients with PUK refractory to standard systemic treatment.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.3576

#### AB0338 HEADS-UP! SARCOIDOSIS AND RHEUMATOID ARTHRITIS CO-EXIST

L. Zickuhr, R. Hajj-Ali. *Rheumatology, Cleveland Clinic Foundation, Cleveland, United States*

**Background:** Sarcoidosis and rheumatoid arthritis (RA) uncommonly co-occur. How dual diagnosis affects these patients' clinical phenotype is unknown.

**Objectives:** To characterize the clinical and laboratory phenotype and to increase awareness of the coexistence of sarcoidosis and RA.

**Methods:** We searched PubMed from 1980–2016 for relevant articles using key words "sarcoidosis" and "rheumatoid arthritis," excluding cases with tumor necrosis factor inhibitors. We found 12 cases, omitted 5 lacking clinical detail, and added 2 from our experience at the Cleveland Clinic. Clinical features, laboratory and imaging findings were reviewed and summarized.

**Results:** Females comprised 7/9 cases (77%). Our cases are the first to describe men with dual diagnosis. Of the 8 cases reporting ethnicity, 4 (50%) were white. The mean age at time of diagnosis was 35.3 years for RA and 51.0 years for sarcoidosis. In 5/9 cases (55%), RA preceded sarcoidosis. RA affected the hands in 8/9 patients (88.9%). Of the 8 cases reporting symptoms of sarcoidosis, 5 (62.5%) had dyspnea. All cases (100%) had elevated rheumatoid factor (RF) and, when checked, anti-citrullinated peptide (anti-CCP) antibodies. Angiotensin converting enzyme (ACE) was elevated in 6/9 patients (66.6%). Of the 5 patients with joint imaging, 4 (80%) had inflammatory changes. All sarcoidosis (100%) was biopsy-proven. One case (11.1%) demonstrated concomitant pulmonary RA and sarcoidosis.

**Conclusions:** Sarcoidosis and RA coexist in seropositive patients, most commonly in women in their fourth through sixth decades of life. RA preceded sarcoidosis about half the time. Hand arthritis and dyspnea were the most common symptoms for RA and sarcoidosis, respectively. Awareness of this dual diagnosis may help identify RA and sarcoidosis earlier and prevent treatment delay.

#### References:

- [1] Enzenauer RJ and West SG. Sarcoidosis in autoimmune disease. *Arth & Rheum*, 1992; 22(1):1–17.
- [2] Menard O, et al. Association of histologically proven rheumatoid arthritis with pulmonary sarcoidosis. *Eur Respir J*, 1995; 8:472–3.
- [3] Kobak S, et al. Co-occurrence of rheumatoid arthritis and sarcoidosis. *BMJ Case Rep*, 2015;1–3.
- [4] Kucera, MRF. A possible association of rheumatoid arthritis and sarcoidosis. *Chest*, 1989; 95:604–06.
- [5] Leo G, et al. Simultaneous pulmonary involvement, histologically proven, of sarcoidosis and rheumatoid arthritis. *Clin Exp Rheumatol*, 2009;27(1):164.
- [6] Takashita M, et al. Mutilating rheumatoid arthritis associated with sarcoidosis: A case report. *Clin rheum*, 1995;14(5):576–9.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.5401

#### AB0339 COMORBIDITIES AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS PATIENTS

L.V. Khimion<sup>1</sup>, I.V. Klymas<sup>1</sup>, I.M. Naishetnik<sup>2</sup>. <sup>1</sup>Department of Family Medicine, Shupyk National Medical Academy of Postgraduate Education; <sup>2</sup>Kyiv Regional Clinical Hospital, Kyiv, Ukraine

**Background:** It is well known, that atherosclerosis associated cardiovascular diseases in many cases determine the life expectancy in RA patients. At the same time, risk factors which promote the development of premature atherosclerosis, including comorbidities, remain uncertain.

**Objectives:** to analyze comorbid conditions in RA patients under age of 50 years and assess their impact on the vascular wall (evaluated by ultrasound investigation of the carotid arteries).

**Methods:** The study was conducted at the Department of Family Medicine, Shupyk NMAPE at the Kyiv Regional Clinical Hospital. The study included 126 RA patients, aged from 18 to 49 years (women - 102 (81%), men - 24 (19%), average age 43.82±8.8 years, who provided written consent to participate in research. As a control group 30 persons without any autoimmune diseases (women - 25 (83.3%) men - 5 (16.7%), average age 42.4±8.6 years) were examined.

All RA patients and control group underwent comprehensive clinical, laboratory and instrumental examination to identify comorbid conditions including evaluation of atherogenesis by use of ultrasound examination of the carotid arteries with intima-media thickness (IMT) measurement and atherosclerosis plaques (AP) assessment.

**Results:** The frequency of identified comorbid conditions and diseases in RA patients and control group are presented in Table 1.

The average number of comorbid diseases/conditions per RA patient significantly exceeded its number in controls (4.13 and 1.67 respectively,  $p < 0.05$ ); most fre-

Table 1. The frequency of comorbidities in RA patients and control group

Diseases and conditions	RA (n=126)		Control (n=30)	
	n	%	n	%
Coronary heart disease	12	9.52*	0	0
Arterial hypertension	47	37.30*	0	0
Neurocirculatory asthenia	2	1.58*	1	3.3
Dyslipidemia	76	60.32*	2	6.67
Peptic ulcer	6	4.76*	1	3.30
Chronic gastritis	29	23.00	3	10.0
Chronic pancreatitis	19	15.08	5	16.67
Nonalcoholic fatty liver disease	77	61.11*	2	6.67
Cholesterosis of the gallbladder	38	30.16*	1	3.33
Chronic cholecystitis	46	36.51*	3	10.00
Gall stones	8	8.25*	0	0
Diabetes mellitus type 2	3	2.38*	0	0
Diffuse goiter	5	3.97*	0	0
Autoimmune thyroiditis	35	27.77*	1	3.33
Chronic obstructive pulmonary disease	5	3.97	4	13.33
Osteoarthritis of the spine	42	33.33	9	30.00
Chronic kidney disease	5	3.97	1	3.33
Abdominal obesity	21	16.67	4	13.33

\*The difference between groups is significant,  $p < 0.05$ .

quently among RA patients was determined: dyslipidemia (60.32%), nonalcoholic fatty liver disease (61.11%), chronic cholecystitis (36.51%), cholesterosis of the gallbladder (30.16%), hypertension (37.30%), autoimmune thyroiditis (27.77%), spinal osteoarthritis (33.33%).

Results of the carotid ultrasonography and assessment of atherosclerosis surrogate markers (IMT, AP) showed higher severity of atherosclerotic process in patients with RA compared to controls; the most important risk factors for increasing IMT and atherosclerotic plaques in carotid arteries were dyslipidemia, autoimmune thyroiditis with hypothyroidism and nonalcoholic fatty liver disease.

**Conclusions:** Patients with RA have a higher frequency of comorbid conditions and diseases than controls without RA; some of comorbidities have significant influence on atherogenesis; RA patients require a multidisciplinary and holistic approach for effective management of their health related problems.

#### References:

- [1] Characteristics of comorbid stenov u hvorih on rheumatoid arthritis. Characteristics of comorbid conditions in patients with rheumatoid arthritis. *Family Medicine* 2015;3(59):219-222.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.3027

#### AB0340 CLINICAL EFFICACY OF STATINS IN PATIENTS WITH RHEUMATOID ARTHRITIS

L. Mikulets, T. Ilashchuk. *Department of Propedeutics of Internal Diseases, Higher State Educational Establishment of Ukraine "Bukovinian State Medical University", Chernivtsi, Ukraine*

**Background:** Cardiovascular disease (CVD) is a major cause of mortality in patients with rheumatoid arthritis (RA). In the literature there are conflicting data on the use of statins in patients with RA, indicating a lack of attention to the issue of prevention of CVD in this category of patients.

**Objectives:** The aim of the study was to improve the efficiency of the treatment of rheumatoid arthritis by including to the basic treatment rosuvastatin.

**Methods:** The study included 43 patients with RA. A survey conducted by the protocol patients (DAS28 index, visual analog scale (VAS), morning stiffness). The study of lipid metabolism included: determining the level of total cholesterol (total cholesterol), HDL cholesterol (HDL) and low density (LDL), atherogenic index (AI), triglycerides (TG). Total cardiovascular risk assessment was performed using a table SCORE. Surveyed patients divided into groups: primary (n=20) (basic therapy and rosuvastatin, 10 mg 1 time per day) and comparison (n=23) (basic therapy that included methotrexate, non-steroidal anti-inflammatory drugs, glucocorticoids in medium therapeutic doses).

**Results:** As a result of the treatment found that patients with a primary and group comparison, there was a positive dynamics of clinical indicators of inflammatory activity (DAS28, VAS, morning stiffness). In the study group experienced a significant decrease ( $p < 0.05$ ) at the same time as in the comparison group had a tendency to decrease. Noted a reduction parameters: CRP ( $\Delta_1$ 37% main group and the comparison group  $\Delta_2$ 21%), ESR ( $\Delta_1$ 39% and  $\Delta_2$ 26% respectively). Also noted the changes in the lipid profile. Significantly decreased in the study group performance total cholesterol ( $\Delta_1$ 31% versus  $\Delta_2$ 15%), LDL cholesterol ( $\Delta_1$ 19% against  $\Delta_2$ 8%) and AI ( $\Delta_1$ 29% and  $\Delta_2$ 16% respectively).

**Conclusions:** Inclusion in the complex therapy of patients with RA statins contributes to a significant reduction in total cholesterol, LDL cholesterol, and positively affects the activity of the process, reducing the levels of acute phase proteins. Additional indications for the purpose of statins have high activity process and late onset. The use of statins in RA, given their lipid-lowering and anti-inflammatory effects, may be an effective means for the successful prevention of cardiovascular complications.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.5983